+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID05303519

Evaluating Safusidenib Safety and Effectiveness in Adults with IDH1-Mutant Gliomas Including Astrocytoma and Oligodendroglioma

Led by Nuvation Bio Inc. · Updated on 2026-10-19

365

Participants Needed

61

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating safusidenib, an investigational drug, in participants with IDH1-mutant gliomas, including Grade 2, Grade 3, and Grade 4 astrocytomas and oligodendrogliomas. The study is divided into three parts Part 1 assesses safusidenibs safety, pharmacokinetics, and initial efficacy in recurrent or progressive gliomas Part 2 compares safusidenib to placebo as maintenance therapy after standard radiation and chemotherapy in high-risk astrocytoma and Part 3 examines safusidenib in participants with recurrent oligodendroglioma who have only had surgery. This Phase 3 trial uses randomized, double-blind, and open-label designs depending on the study part. In Part 1, participants receive one of several oral doses of safusidenib daily for 28-day cycles to study dose effects on safety and drug behavior. Part 2 participants are randomly assigned to safusidenib or placebo taken orally twice daily in continuous 28-day cycles until disease progression or other reasons for stopping treatment. Part 3 participants receive safusidenib orally twice daily continuously until disease progression or discontinuation. The trial monitors treatment effects through regular tumor assessments and survival follow-up. Participants undergo screening to confirm eligibility and molecular tumor markers. During the study, they receive oral medication and have tumor response evaluations conducted regularly by central review and investigators. Safety is monitored by tracking adverse events and tolerability. The trial measures outcomes such as progression-free survival, response rates, and overall survival over periods averaging from 18 months to 7 years, depending on the study part. Quality of life and seizure activity are also assessed.

CONDITIONS

Brief Title

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

Research Team

C

Clinical Trials at Nuvation Bio

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here